Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101564974 Publication Model: Print Cited Medium: Internet ISSN: 2159-2535 (Electronic) Linking ISSN: 21592527 NLM ISO Abbreviation: Biomatter Subsets: MEDLINE

Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience

Drug Delivery Systems*; Cryoprotective Agents/*chemistry ; Insulin/*administration & dosage ; Lactic Acid/*chemistry ; Nanoparticles/*chemistry ; Polyglycolic Acid/*chemistry; Freeze Drying ; Humans ; Insulin/chemistry ; Microscopy, Electron, Scanning ; Microscopy, Electron, Transmission ; Nanomedicine ; Polylactic Acid-Polyglycolic Acid Copolymer ; Porosity ; Recombinant Proteins/administration & dosage ; Surface Properties ; Surface-Active Agents/chemistry ; Time Factors

PLGA nanoparticles are useful to protect and deliver proteins in a localized or targeted manner, with a long-term systemic delivery pattern intended to last for a period of time, depending on polymer bioerosion and biodegradability. However, the principal concern regarding these carriers is the hydrolytic instability of polymer in aqueous suspension. Freeze-drying is a commonly used method to stabilize nanoparticles, and cryoprotectants may be also used, to even increase its physical stability. The aim of the present work was to analyze the influence of cryoprotectants on nanoparticle stability and porosity after freeze-drying, which may influence protein release and stability. It was verified that freeze-drying significantly increased the number of pores on PLGA-NP surface, being more evident when cryoprotectants are added. The presence of pores is important in a lyophilizate to facilitate its reconstitution in water, although this may have consequences to protein release and stability. The release profile of insulin encapsulated into PLGA-NP showed an initial burst in the first 2 h and a sustained release up to 48 h. After nanoparticles freeze-drying the insulin release increased about 18% in the first 2 h due to the formation of pores, maintaining a sustained release during time. After freeze-drying with cryoprotectants, the amount of insulin released was higher for trehalose and lower for sucrose, glucose, fructose and sorbitol comparatively to freeze-dried PLGA-NP with no cryoprotectant added. Besides the porosity, the ability of cryoprotectants to be adsorbed on the nanoparticles surface may also play an important role on insulin release and stability.

Erratum in: Biomatter. 2015;5:e1115711. doi: 10.1080/21592535.2015.1115711. (PMID: 26594851)

Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18. (PMID: 19782542)
Drug Deliv Transl Res. 2011 Aug;1(4):299-308. (PMID: 25788364)
Adv Drug Deliv Rev. 2006 Dec 30;58(15):1688-713. (PMID: 17118485)
Int J Pharm. 2005 Sep 14;301(1-2):161-9. (PMID: 16026945)
J Control Release. 1998 Jan 2;50(1-3):31-40. (PMID: 9685870)
Eur J Pharm Biopharm. 2000 Nov;50(3):379-87. (PMID: 11072195)
Int J Pharm. 2008 Feb 28;350(1-2):14-26. (PMID: 18162341)
J Microencapsul. 1997 Nov-Dec;14(6):777-87. (PMID: 9394259)
Eur J Pharm Sci. 1999 May;8(2):99-107. (PMID: 10210732)
J Biomed Nanotechnol. 2009 Feb;5(1):45-53. (PMID: 20055105)
Eur J Pharm Biopharm. 2011 Jun;78(2):248-63. (PMID: 21426937)
Int J Pharm. 2006 Dec 11;327(1-2):153-9. (PMID: 16935443)
J Pharm Pharmacol. 2005 Jun;57(6):699-707. (PMID: 15969924)
Biomed Chromatogr. 2006 Sep;20(9):898-903. (PMID: 16389645)
Int J Pharm. 2002 Feb 21;233(1-2):239-52. (PMID: 11897428)
Eur J Pharm Biopharm. 2012 May;81(1):57-63. (PMID: 22306701)
J Control Release. 2012 Jul 20;161(2):505-22. (PMID: 22353619)
J Control Release. 2002 Jul 18;82(1):105-14. (PMID: 12106981)
Biomaterials. 1996 Nov;17(22):2191-7. (PMID: 8922605)
Biophys J. 1996 Oct;71(4):2022-32. (PMID: 8889176)
J Fluoresc. 1993 Dec;3(4):215-7. (PMID: 24234896)
Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422. (PMID: 15719481)
Eur J Pharm Biopharm. 2009 Jun;72(2):428-37. (PMID: 19462479)
Eur J Pharm Biopharm. 1998 May;45(3):221-9. (PMID: 9653626)
J Microencapsul. 2005 Sep;22(6):593-601. (PMID: 16401576)
Expert Opin Drug Deliv. 2005 Nov;2(6):1029-37. (PMID: 16296807)
Biophys J. 1996 Oct;71(4):2087-93. (PMID: 8889183)
Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96. (PMID: 11311991)
Int J Pharm. 2003 Nov 6;266(1-2):51-60. (PMID: 14559393)
Pharm Res. 1999 Jun;16(6):859-66. (PMID: 10397606)
Int J Pharm. 2000 Aug 10;203(1-2):1-60. (PMID: 10967427)

Keywords: PLGA; cryoprotectants; freeze-drying; insulin; nanoparticles; porosity; release profile; surface

0 (Cryoprotective Agents)
0 (Insulin)
0 (Recombinant Proteins)
0 (Surface-Active Agents)
1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
26009-03-0 (Polyglycolic Acid)
33X04XA5AT (Lactic Acid)

Date Created: 20130320 Date Completed: 20140320 Latest Revision: 20211021

20250114

PMC3568117

10.4161/biom.23246

23507897